Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer Clinical Trial

Official title:

Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02541370
• Other study ID #: s2015-080-03
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 2015
• Est. completion date: June 2019

Study information

• Verified date: June 2015
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.

PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

Description:

I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD133 (cluster of differentiation antigen 133 ) vector (referred to as CART-133 cells).

II. Determine duration of in vivo survival of CART-133 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-133 TCR (T-cell receptor) zeta:CD137 and TCR zeta cells over time.

SECONDARY OBJECTIVES:

I. For patients with detectable disease, measure anti-tumor response due to CART-133 cell infusions.

II. To determine if the CD137 transgene is superior to the TCR zeta only transgene as measured by the relative engraftment levels of CART-133 TCR zeta:CD137 and TCR zeta cells over time.

III. Estimate relative trafficking of CART-133 cells to tumor in bone marrow and lymph nodes.

IV. For patients with stored or accessible tumor cells determine tumor cell killing by CART-133 cells in vitro.

V. Determine if cellular or humoral host immunity develops against the murine anti-CD133, and assess correlation with loss of detectable CART-133 (loss of engraftment).

VI. Determine the relative subsets of CART-133 T cells (Tcm, Tem, and Treg).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Chemotherapy refractory or relapsed CD133-positive liver cancer, pancreatic cancer, brain tumor ,breast cancer, ovarian tumors, colorectal cancer and acute leukemia.

2. Patients must be 18 years of age or older.

3. Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-2.

4. Patients must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters:

Absolute neutrophil count greater than 1500/mm3. Platelet count greater than 100,000/mm3. Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).

Total bilirubin < 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m.

5. Seronegative for HIV antibody.

6. Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.

7. Patients must be willing to practice birth control during and for four months following treatment. NOTE: women of child-bearing age must have evidence of negative pregnancy test.

8. Patients must be willing to sign an informed consent.

Exclusion Criteria:

• 1. Patients with life expectancy less than 12 months will be excluded. 2. Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.

3. Patients with any of the following pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), < 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) < 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.

4. Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.

5. Pregnant and/or lactating women will be excluded. 6. Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.

7. Patients with any type of primary immunodeficiencies will be excluded from the study.

8. Patients requiring corticosteroids (other than inhaled) will be excluded. 9. Patients with history of T cell tumors will be excluded. 10. Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.

11. Patients with relapsed acute leukemia after allogeneic stem cell transplantation

Related Conditions & MeSH terms

• Acute Myeloid and Lymphoid Leukemias
• Brain Tumor
• Breast Cancer
• Colorectal Cancer
• Leukemia, Lymphoid
• Liver Cancer
• Ovarian Neoplasms
• Ovarian Tumor
• Pancreatic Cancer

Intervention

Biological:
• anti-CD133-CAR vector-transduced T cells
genetically engineered lymphocyte therapy

Locations

Country	Name	City	State
China	Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	in vivo existence of CART133		1 year
Primary	Occurrence of study related adverse events	defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical	Until week 24
Secondary	Anti-tumor responses to CART-133 cell infusions		up to 24 weeks